Salesforce (NYSE: $CRM) Stock: Record Q3 & Breakout Setup

268
Salesforce (NYSE: CRM) delivered a standout fiscal Q3 2026, posting record results driven by explosive growth in Agentforce and Data 360, its fastest-scaling AI and data platforms. Revenue rose 9% year-over-year to $10.3 billion, with subscription and support revenue reaching $9.7 billion, up 10%. The company generated a strong $2.3 billion in operating cash flow, a 17% annual increase, while free cash flow surged 22% to $2.2 billion.

A major highlight was the accelerating expansion in performance obligations. Current RPO hit $29.4 billion, up 11% Y/Y, while total RPO climbed to $59.5 billion, signaling strong visibility into future revenue. Salesforce also raised full-year FY26 guidance to as high as $41.55 billion, supported by the newly completed Informatica acquisition, which enhances the company’s enterprise data capabilities across governance, integration, metadata, and MDM.

Agentforce and Data 360 were the clear growth engines. Combined ARR reached $1.4 billion, soaring 114% Y/Y. Agentforce ARR alone surpassed half a billion, up 330% Y/Y, with over 9,500 paid deals and more than 3.2 trillion tokens processed through its LLM gateway. Data 360 saw massive record ingestion growth, including a 341% spike via Zero Copy. This adoption momentum strengthens Salesforce’s long-term target of $60B+ organic revenue and its FY30 Profitable Growth Framework.

TECHNICALS

The chart shows CRM reclaiming demand after months of compression inside a descending trendline. Price recently bounced sharply from the $225–$235 support zone, where accumulation has been active for nearly two years. The breakout attempt above the long-term trendline is now in focus.

If price secures a clean close above $255–$260, upside targets open toward $290, and ultimately the $369 all-time-high zone. RSI sits mid-range, signaling room for expansion, while MACD hovers near a bullish cross. Failure to hold above $255 could re-expose the $225 demand region.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.